|
1
|
Kubota Y: Tumor angiogenesis and
anti-angiogenic therapy. Keio J Med. 61:47–56. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Abdelrahim M, Konduri S, Basha R, Philip
PA and Baker CH: Angiogenesis: An update and potential drug
approaches. Int J Oncol. 36:5–18. 2010.PubMed/NCBI
|
|
3
|
Su M, Huang J, Li J, Qin X, Tang X, Jin F,
Chen S, Jiang C, Zou Z, Peng K, et al: ZLM-7 exhibits
anti-angiogenic effects via impaired endothelial cell function and
blockade of VEGF/VEGFR-2 signaling. Oncotarget. 7:19018–19030.
2016.PubMed/NCBI
|
|
4
|
Saraswati S, Kanaujia PK, Kumar S, Kumar R
and Alhaider AA: Tylophorine, a phenanthraindolizidine alkaloid
isolated from Tylophora indica exerts antiangiogenic and antitumor
activity by targeting vascular endothelial growth factor receptor
2-mediated angiogenesis. Mol Cancer. 12:822013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fiskus W, Wang Y, Joshi R, Rao R, Yang Y,
Chen J, Kolhe R, Balusu R, Eaton K, Lee P, et al: Cotreatment with
vorinostat enhances activity of MK-0457 (VX-680) against acute and
chronic myelogenous leukemia cells. Clin Cancer Res. 14:6106–6115.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Doggrell SA: Dawn of Aurora kinase
inhibitors as anticancer drugs. Expert Opin Investig Drugs.
13:1199–1201. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cheetham GM, Charlton PA, Golec JM and
Pollard JR: Structural basis for potent inhibition of the Aurora
kinases and a T315I multi-drug resistant mutant form of Abl kinase
by VX-680. Cancer Lett. 251:323–329. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lin YG, Immaneni A, Merritt WM, Mangala
LS, Kim SW, Shahzad MM, Tsang YT, Armaiz-Pena GN, Lu C, Kamat AA,
et al: Targeting aurora kinase with MK-0457 inhibits ovarian cancer
growth. Clin Cancer Res. 14:5437–5446. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jin X, Mo Q, Zhang Y, Gao Y, Wu Y, Li J,
Hao X, Ma D, Gao Q and Chen P: The p38 MAPK inhibitor BIRB796
enhances the antitumor effects of VX680 in cervical cancer. Cancer
Biol Ther. 17:566–576. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li Y, Zhang ZF, Chen J, Huang D, Ding Y,
Tan MH, Qian CN, Resau JH, Kim H and The BT: VX680/MK-0457, a
potent and selective Aurora kinase inhibitor, targets both tumor
and endothelial cells in clear cell renal cell carcinoma. Am J
Transl Res. 2:296–308. 2010.PubMed/NCBI
|
|
11
|
Xu DR, Huang S, Long ZJ, Chen JJ, Zou ZZ,
Li J, Lin DJ and Liu Q: Inhibition of mitotic kinase Aurora
suppresses Akt-1 activation and induces apoptotic cell death in
all-trans retinoid acid-resistant acute promyelocytic leukemia
cells. J Transl Med. 9:742011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Giles FJ, Swords RT, Nagler A, Hochhaus A,
Ottmann OG, Rizzieri DA, Talpaz M, Clark J, Watson P, Xiao A, et
al: MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in
patients with BCR-ABL T315I leukemia. Leukemia. 27:113–117. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Pezzani R, Rubin B, Bertazza L, Redaelli
M, Barollo S, Monticelli H, Baldini E, Mian C, Mucignat C, Scaroni
C, et al: The aurora kinase inhibitor VX-680 shows anti-cancer
effects in primary metastatic cells and the SW13 cell line. Invest
New Drugs. 34:531–540. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sun JM, Yang LN, Xu H Chang B, Wang HY and
Yang G: Inhibition of Aurora A promotes chemosensitivity via
inducing cell cycle arrest and apoptosis in cervical cancer cells.
Am J Cancer Res. 5:1133–1145. 2015.PubMed/NCBI
|
|
15
|
Yao R, Zheng J, Zheng W, Gong Y, Liu W and
Xing R: VX680 suppresses the growth of HepG2 cells and enhances the
chemosensitivity to cisplatin. Oncol Lett. 7:121–124. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bertolini F, Marighetti P, Martin-Padura
I, Mancuso P, Hu-Lowe DD, Shaked Y and D'Onofrio A: Anti-VEGF and
beyond: shaping a new generation of anti-angiogenic therapies for
cancer. Drug Discov Today. 16:1052–1060. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Roskoski R Jr: Vascular endothelial growth
factor (VEGF) signaling in tumor progression. Crit Rev Oncol
Hematol. 62:179–213. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cui HJ, Yang AL, Zhou HJ, Wang C, Luo JK,
Lin Y, Zong YX and Tang T: Buyang huanwu decoction promotes
angiogenesis via vascular endothelial growth factor receptor-2
activation through the PI3K/Akt pathway in a mouse model of
intracerebral hemorrhage. BMC Complement Altern Med. 15:912015.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wu XY, Xu H, Wu ZF, Chen C, Liu JY, Wu GN,
Yao XQ, Liu FK, Li G and Shen L: Formononetin, a novel FGFR2
inhibitor, potently inhibits angiogenesis and tumor growth in
preclinical models. Oncotarget. 6:44563–44578. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sharma S, Guru SK, Manda S, Kumar A Mintoo
MJ, Prasad VD, Sharma PR, Mondhe DM, Bharate SB and Bhushan S: A
marine sponge alkaloid derivative 4-chloro fascaplysin inhibits
tumor growth and VEGF mediated angiogenesis by disrupting
PI3K/Akt/mTOR signaling cascade. Chem Biol Interact. 275:47–60.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yan M, Wang C, He B, Yang M, Tong M, Long
Z, Liu B, Peng F, Xu L, Zhang Y, et al: Aurora-A Kinase: A potent
oncogene and target for cancer therapy. Med Res Rev. 36:1036–1079.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
D'Assoro AB, Haddad T and Galanis E:
Aurora-A kinase as a promising therapeutic target in cancer. Front
Oncol. 5:2952016.PubMed/NCBI
|
|
23
|
Portella G, Passaro C and Chieffi P:
Aurora B: A new prognostic marker and therapeutic target in cancer.
Curr Med Chem. 18:482–96. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Seymour JF, Kim DW, Rubin E, Haregewoin A,
Clark J, Watson P, Hughes T, Dufva I, Jimenez JL, Mahon FX, et al:
A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant
chronic myelogenous leukemia and philadelphia chromosome-positive
acute lymphoblastic leukemia. Blood Cancer J. 4:e2382014.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ponce ML: Tube formation: An in vitro
matrigel angiogenesis assay. Methods Mol Biol. 467:183–188. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kim ES, Serur A, Huang J, Manley CA,
McCrudden KW, Frischer JS, Soffer SZ, Ring L, New T, Zabski S, et
al: Potent VEGF blockade causes regression of coopted vessels in a
model of neuroblastoma. Proc Natl Acad Sci USA. 99:11399–11404.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Saraswati S, Kumar S and Alhaider AA:
α-santalol inhibits the angiogenesis and growth of human prostate
tumor growth by targeting vascular endothelial growth factor
receptor 2-mediated AKT/mTOR/P70S6K signaling pathway. Mol Cancer.
12:1472013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Du J, Wang R, Yin L, Fu Y, Cai Y, Zhang Z
and Liang A: BmK CT enhances the sensitivity of
temozolomide-induced apoptosis of malignant glioma U251 cells in
vitro through blocking the AKT signaling pathway. Oncol Lett.
15:1537–1544. 2018.PubMed/NCBI
|
